On May 4, 2026, the U.S. Supreme Court (SCOTUS) granted an emergency administrative stay to a pair of abortion pill manufacturers. This paused a May 1 ruling by the Fifth Circuit Court of Appeals that reinstated a rule requiring any prescription for mifepristone to include an in-person visit with a healthcare provider, rather than being available by mail after a telehealth consultation. The Court’s order, issued by Justice Samuel Alito, pauses the ban until 5 p.m. on May 11, with responses due by the same time on May 7.
The state of Louisiana is the plaintiff in the latest battle in the ongoing war between anti-abortion advocates and those fighting to preserve abortion rights and women’s health choices, suing the Food and Drug Administration (FDA) over the availability of the abortion drug mifepristone through the mail. Three years after SCOTUS struck down Roe v. Wade and returned primary control of abortion regulation to the states, the legal landscape regarding reproductive rights remains a tangled morass. What the future holds is unknown, but the ability to get pills for a medication abortion will remain available through telemedicine until at least May 11.
Nope, the Fight Is Far From Over
SCOTUS’s court decision in 2023’s Dobbs v. Jackson Women’s Health rescinded federal constitutional protections for a woman’s right to choose. This put control of abortion access in the hands of the states, many of which either had trigger bans go into effect or passed new laws making abortions difficult or illegal to obtain.
Abortions are available in two methods: surgical or medical (chemical). The former is a surgical procedure performed on an anesthetized patient. Medical abortions consist of abortion medication given in a two-pill regimen. Used for early-stage pregnancies, mifepristone is administered first, followed by a dose of misoprostol. The pills have an extremely high safety record and account for close to two-thirds of each year’s abortions. About 25% of all abortions involve a telehealth appointment.
While mifepristone was originally subject to an in-person dispensing requirement, the FDA permitted telehealth prescriptions and mail delivery during the COVID‑19 pandemic. In 2023, the agency formally revised mifepristone’s Risk Evaluation and Mitigation Strategy (REMS) to allow continued access by mail and at certified pharmacies. This allowed patients in states with restrictive abortion laws, like Texas and Louisiana, to continue accessing pills for medication abortions.
Multiple lawsuits over the past several years have targeted medication abortion and mail or telehealth access to mifepristone. In earlier litigation brought by anti-abortion doctors, the Supreme Court issued an emergency order in 2023 that kept Mifepristone available under the FDA’s existing rules and later rejected those doctors’ challenge on standing grounds. Separately, the FDA is conducting an additional safety review of mifepristone that courts and parties expect to conclude in late 2026, and it has not reimposed the old in-person dispensing requirement while that review continues. In the meantime, Louisiana’s complaint is the latest contender in the judicial ring.
The Fight Goes On … And On … And On
Louisiana has some of the strictest abortion laws in the country. The procedure is only permitted to save the mother’s life, if the fetus is “medically futile,” or in case of an ectopic pregnancy. Doctors who perform an illegal abortion in the state face up to 10 years in prison and fines of up to $10,000. In addition, Governor Jeff Landry signed a law in 2024 that classified mifepristone and misoprostol as dangerous controlled substances, making it a crime to possess or deliver the drugs to anyone in the state.
The state's 2025 lawsuit claims that the FDA violated the Administrative Procedure Act (APA) by allowing the drugs to be distributed without an in-person visit. Louisiana argues that the agency relied on allegedly flawed data and cites the state’s expenses in paying medical bills for women it says were harmed by mifepristone, based on two cases of serious side effects.
Two mifepristone manufacturers, Danco Laboratories and GenBioPro, were permitted to intervene as defendants. A federal district court concluded that Louisiana was likely to succeed on its claim but declined to block the FDA’s 2023 mifepristone rules, finding that the balance of equities and the public interest weighed in favor of leaving those rules in place while the FDA review continued.
Louisiana swiftly filed an emergency appeal under 5 U.S.C. § 705 in the Fifth Circuit Federal Appeals Court, which overruled the lower court’s decision on May 1, 2026. This was countered by Danco’s and Genbiopro’s application for an administrative stay later that same day, which accused the conservative-leaning Fifth Circuit of making an “unprecedented” overreach against the FDA’s authority and established drugs. Justice Alito's stay was issued on Monday, lifting the ban after a weekend of uncertainty.
What happens next is anybody’s guess. The stay could remain in effect until the FDA finishes its review, or the courts may decide that Louisiana’s interests in enforcing its abortion laws outweigh the arguments for continued nationwide access to medication abortion by mail and telehealth. In any case, next Monday’s deadline is likely to draw intense attention from both sides.
Related Resources
- Why Was Roe v. Wade Overturned? (FindLaw’s Supreme Court Insights)
- States Square Off in Legal Battles Over Abortion Rights and Shield Laws (FindLaw’s Law and Daily Life)
- Abortion History in the U.S. (FindLaw’s Reproductive Rights)
